Lenalidomide gastric retention sustained release tablet and preparation method thereof

A technology for lenalidomide and sustained-release tablets, which is applied in the field of lenalidomide gastroretentive sustained-release tablets and the preparation thereof, can solve the problems of unfavorable formulation stability, unfavorable production, poor stability and the like, and achieves high drug bioavailability , Small side effects, high compliance effect

Active Publication Date: 2018-09-11
AC PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Commonly used bleaching aids include stearyl alcohol, stearic acid, glyceryl monostearate, glyceryl behenate, carnauba wax, white wax, hydrogenated vegetable oil, etc. These substances have poor stability, low melting point, and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lenalidomide gastric retention sustained release tablet and preparation method thereof
  • Lenalidomide gastric retention sustained release tablet and preparation method thereof
  • Lenalidomide gastric retention sustained release tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0048] Example 1

[0049]

[0050] Information on release enhancers and sustained release materials:

[0051] Product name

[0052] Lenalidomide is B crystal form, the weight average molecular weight of hydroxypropyl methylcellulose K200M is about 1,200,000. Tablet preparation method: Weigh the above raw materials except magnesium stearate, and mix them evenly after passing through a 60 mesh sieve. , Then add magnesium stearate to mix properly and compress into tablets, the tablet hardness is 9~10kg / cm 2 , Tablet density 0.991g / cm 3 .

[0053] Example 1 Floating performance of gastric floating sustained-release tablets: The tablets float quickly after being put into the dissolution cup, and continue to float in the dissolution medium for at least 24 hours.

[0054] The release measurement results of the lenalidomide gastric retention sustained-release tablets prepared according to Example 1:

[0055] Time(h)

[0056] The test results show that lenalidomide gastric retention susta...

Example Embodiment

[0057] Example 2

[0058]

[0059]

[0060] Information on release enhancers and sustained release materials:

[0061] Product name

[0062] Lenalidomide is in the A crystal form, and the weight average molecular weight of hydroxypropyl methylcellulose K250 is about 200,000. Preparation method: weigh the above raw materials except sodium stearyl fumarate, and mix them evenly after passing through a 60 mesh sieve. , Add sodium stearyl fumarate properly and mix it into tablets, the tablet hardness is 3~4kg / cm 2 , Tablet density

[0063] 0.755g / cm 3 .

[0064] Example 2 Floating performance of gastric floating sustained-release tablets: The tablets float quickly after being put into the dissolution cup, and continue to float in the dissolution medium for at least 24 hours.

[0065] The release measurement results of the lenalidomide gastric retention sustained-release tablets prepared according to Example 2:

[0066] Time(h)

[0067] The test results show that lenalidomide gastric re...

Example Embodiment

[0068] Example 3

[0069]

[0070] Information on release enhancers and sustained release materials:

[0071]

[0072]

[0073] Lenalidomide is crystalline form II, and the weight average molecular weight of hydroxypropyl methylcellulose K750 is about 250,000. Preparation method: Weigh the above-mentioned raw and auxiliary materials except talc, pass through a 60-mesh sieve and mix well, then add talc The powder is properly mixed and compressed into tablets, the tablet hardness is 5~6kg / cm 2 , Tablet density 0.949g / cm 3 .

[0074] Example 3 Floating performance of gastric floating sustained-release tablets: The tablets float quickly after being put into the dissolution cup, and continue to float in the dissolution medium for at least 24 hours.

[0075] The release determination results of the lenalidomide gastric retention sustained-release tablets prepared according to Example 3:

[0076] Time(h)

[0077] The test results show that lenalidomide gastric retention sustained-release t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Bulk densityaaaaaaaaaa
Bulk densityaaaaaaaaaa
Viscosityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a lenalidomide gastric retention sustained release tablet and a preparation method thereof. The sustained release tablet comprises 3-14 wt% of lenalidomide, 14-68 wt% of a low-bulk density release promoter, 23-70 wt% of a low-bulk density sustained release material, and the balance of other pharmaceutically acceptable auxiliary materials, wherein the bulk density of the release promoter is 0.24-0.52 g/cm<3>; and the bulk density of the sustained release material is 0.29-0.51 g/cm<3>. The sustained-release tablet is in a floating state in the stomach environment, is notdirectly excluded from the stomach due to gastric emptying, has a gastric retention effect, is not easily discharged with the stomach content, and has high drug bioavailability and small side effects.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a lenalidomide gastric retention sustained-release tablet and a preparation method thereof. Background technique [0002] Lenalidomide is an anti-tumor immunomodulator, which has been widely used clinically in multiple myeloma (MM). It was developed by Celgene and marketed in capsule form. [0003] Commercially available lenalidomide capsules are rapidly absorbed in the gastrointestinal tract after oral administration, the peak blood drug time is 0.5-1.5 hours, and the half-life is about 3 hours. When the dose is 5-50 mg, the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) can increase proportionally with the increase of the dose. However, its blood concentration fluctuates greatly, and its toxic and side effects are obvious, which significantly reduces the number of neutrophils and platelets. Therefore, it is necess...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/454A61K9/22A61K47/38A61P35/00
CPCA61P35/00A61K9/0065A61K9/2054A61K31/454A61K9/2095
Inventor 罗华锋何静瑜谭晓峰赖树挺刘锋
Owner AC PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap